Your browser doesn't support javascript.
loading
COVID-19 and plasma cells: Is there long-lived protection?
Nguyen, Doan C; Lamothe, Pedro A; Woodruff, Matthew C; Saini, Ankur S; Faliti, Caterina E; Sanz, Ignacio; Lee, Frances Eun-Hyung.
Afiliación
  • Nguyen DC; Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Emory University, Atlanta, Georgia, USA.
  • Lamothe PA; Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Emory University, Atlanta, Georgia, USA.
  • Woodruff MC; Division of Rheumatology, Department of Medicine, Emory University, Atlanta, Georgia, USA.
  • Saini AS; Emory Autoimmunity Center of Excellence, Emory University, Atlanta, Georgia, USA.
  • Faliti CE; Lowance Center for Human Immunology, Emory University, Atlanta, Georgia, USA.
  • Sanz I; Division of Rheumatology, Department of Medicine, Emory University, Atlanta, Georgia, USA.
  • Lee FE; Emory Autoimmunity Center of Excellence, Emory University, Atlanta, Georgia, USA.
Immunol Rev ; 309(1): 40-63, 2022 08.
Article en En | MEDLINE | ID: mdl-35801537
ABSTRACT
Infection with SARS-CoV-2, the etiology of the ongoing COVID-19 pandemic, has resulted in over 450 million cases with more than 6 million deaths worldwide, causing global disruptions since early 2020. Memory B cells and durable antibody protection from long-lived plasma cells (LLPC) are the mainstay of most effective vaccines. However, ending the pandemic has been hampered by the lack of long-lived immunity after infection or vaccination. Although immunizations offer protection from severe disease and hospitalization, breakthrough infections still occur, most likely due to new mutant viruses and the overall decline of neutralizing antibodies after 6 months. Here, we review the current knowledge of B cells, from extrafollicular to memory populations, with a focus on distinct plasma cell subsets, such as early-minted blood antibody-secreting cells and the bone marrow LLPC, and how these humoral compartments contribute to protection after SARS-CoV-2 infection and immunization.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: COVID-19 Límite: Humans Idioma: En Revista: Immunol Rev Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Asunto principal: COVID-19 Límite: Humans Idioma: En Revista: Immunol Rev Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos